News

Two Weill Cornell Medicine physician-scientists, Dr. Semra Etyemez and Dr. Jesse Platt, have been honored with prestigious early-career awards from the American Society for Clinical Investigation (ASCI) for 2026.

A new study reveals how bacteria in the gut can help determine whether the amino acid asparagine from the diet will feed tumor growth or activate immune cells against the cancer​, according to researchers at Weill Cornell Medicine.

Awards, honors and achievements for the month of January. 

A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer, according to a study by Weill Cornell Medicine investigators.

Weill Cornell Medicine has received a $5.2 million, initial two-year award  from the Advanced Research Projects Agency for Health (ARPA-H) Lymphatic Imaging, Genomics, and pHenotyping Technologies (LIGHT) program to develop a comprehensive and innovative approach to diagnosing lymphatic disease.

Approximately 88% of adults view opioid overdose deaths as a very serious problem with high agreement across political groups, according to a national survey conducted by Weill Cornell Medicine researchers. However, political differences over who is responsible may shape the country’s next phase of drug policy.

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

Dr. Longman will lead a world-class, multidisciplinary team of women’s health specialists who provide comprehensive health care services, spanning prenatal and postpartum services, gynecologic cancer screenings, treatment of reproductive disorders, family planning and preventative care.

Using participant skin cells reprogrammed into neurons, Weill Cornell Medicine researchers have identified genetic signatures associated with HIV infection that may contribute to the cognitive impairment that often occurs in people living with the disease, even when the virus is controlled.

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

On Dec. 10, first-year Weill Cornell Medical College students memorialized the 28 people who generously donated their bodies to the institution’s Gross Anatomy program.

Pain-sensing neurons in the gut kindle inflammatory immune responses that cause allergies and asthma, according to a new study by Weill Cornell Medicine.

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy.

Awards, honors and achievements for the month of December. 

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more flexible, or plastic, stem-cell-like state in the lymph nodes, according to a new preclinical study from Weill Cornell Medicine investigators. 

A new study from Weill Cornell Medicine uncovers how a viral protein called E4ORF1 precisely activates a specific signaling complex in human blood vessel cells to support cell survival. 

Women with severe coronary heart disease causing narrowing or blockages in the arteries may derive greater long-term benefits from coronary artery bypass grafting compared with percutaneous coronary intervention, also known as stenting, according to a large study by Weill Cornell Medicine investigators.

Weill Cornell Medicine is poised to thrive in the coming years, with a planned expansion of its clinical enterprise serving as an engine for overall institutional growth, Dean Robert Harrington conveyed Dec. 16 during his biannual State of Weill Cornell Medicine address.

From light-activated pain relief to next-generation cancer immunotherapies, scientists and clinicians showcased bold ideas for translating lab discoveries into real-world treatments as part of the Accelerating BioVenture Innovation (ABI) program within Enterprise Innovation at Weill Cornell.

Dr. John Blenis's lab discovered that low levels of folate, a B vitamin essential for cell growth, can trigger specific genetic changes found in lung tumors, establishing a link between nutrition and cancer, which may open new dietary approaches for prevention and treatment.